Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results